Meeting
2024 ASCO Annual Meeting
Prospective evaluation of the effect of 3 days of post-chemotherapy dexamethasone on patient reported symptoms in gynecologic oncology patients treated with carboplatin and paclitaxel.
Authors
Hayley Hart
Drexel University, Philadelphia, PA
Hayley Hart , Christopher Morse , Thomas C. Krivak , Eirwen Murray Miller , Sarah Crafton , Alyssa Wield , Alexander Olawaiye , Ali Imran Amjad , Emily Graham , Tammy Li , Heather English , Donna Marie Kinzler , John Nakayama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5618)
DOI
10.1200/JCO.2024.42.16_suppl.5618
Abstract #
5618
Poster Bd #
489
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.
First Author: Mansoor Raza Mirza
Poster
2023 ASCO Annual Meeting
The FARGO study: Frailty assessment for risk prediction in gynecologic oncology.
First Author: Julie My Van Nguyen
Poster
2022 ASCO Annual Meeting
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
First Author: Katherine Han
Poster
2022 ASCO Annual Meeting
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.
First Author: Andee Dooley